Referências
FDA. FDA approves new HIV drug: Raltegravir tablets used in combination with other antiretroviral agents. Administration USFaD, editor. FDA News; 2007
Markovitz M. Targeting Integrase: Mechanisms of Action and Mechanisms of Resistance to Integrase Inhibitors. Clinical Care Options; 2008.
Charpentier C, Karmockine M, Laureillard D, Tisserand P, Belec L, Weiss L, et al. Drug resistance profiles for the HIV Integrase gene in patients failing Raltegravir salvage therapy. HIV Med. 2008;9:765-70.
Hu Z, Kuritzkes DR. Effect of Raltegravir Resistance Mutations in HIV-1 Integrase on Viral Fitness. J Acquir Immune Defic Syndr. 2010;55:148-55.
Hackett JJ, Swanson P, Harris B, Holzmayer V, Yamaguchi J, Bodelle P, et al. Conf Retr. Opportunistic Infect. Comprehensive evaluation of HIV-1 integrase gene diversity in group m, n, and o viruses. Abstract. 2005;Feb:22-25:366.